This $5 billion biotech home run lasted less than a year

This $5 billion biotech home run lasted less than a year

You can’t completely blame PfizerIt is frames, but rockIt is The $7 billion acquisition of a bowel disease treatment it owned until last year is not a good idea.

In a deal that now resembles a biotech version of “Moneyball,” Roivant announced it was selling an asset it got for free from Pfizer just 11 months ago. (The Wall Street Journal reported on the discussions in July). Big pharma focused on the pharmaceutical industry equivalent of free agent signings will often overlook one of their own promising prospects. In fact, the Republican presidential candidate Vivek Ramaswamy founded Roivant on the idea that pharmaceutical waste can be another company’s treasure. But this one became an All-Star almost instantly.

Copyright ©2023 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8



With a penchant for words, Eleon Smith began writing at an early age. As editor-in-chief of his high school newspaper, he honed his skills telling impactful stories. Smith went on to study journalism at Columbia University, where he graduated top of his class. After interning at the New York Times, Smith landed a role as a news writer. Over the past decade, he has covered major events like presidential elections and natural disasters. His ability to craft compelling narratives that capture the human experience has earned him acclaim. Though writing is his passion, Eleon also enjoys hiking, cooking and reading historical fiction in his free time. With an eye for detail and knack for storytelling, he continues making his mark at the forefront of journalism.
Back to top button